IMV Inc. (OTCPK: IMVI.F)
Health Care · Biotechnology · CA
$0.00
+1500.00% today · -99.9% 1Y
IMV Inc. (OTCPK: IMVI.F) operates in the Biotechnology industry within the Health Care sector. The company is valued at $235.00 and employs 63 people.
Over the last twelve months the share price has lost 99.9%, trading between 0.00 and 0.02.
Tweenvest scores IMV Inc. across four factors: quality 11/100. Its strongest factor is quality.
IMVI.F price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $235.00
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.55
- Dividend yield
- —
- Beta (5Y)
- 4,148.60
- 52-week high
- $0.02
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 14.71M
- Employees
- 63
- Next earnings
- —
About IMV Inc.
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
- ISIN
- CA44974L3011
- Founded
- 2000
- Listed since
- Oct 24, 2007
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.